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Background:  Although  BCG  is  used  as a  vaccine  against  tuberculosis,  it also  protects  against  leprosy.
Previous  evaluation  over  18  years  of an  intervention  of two doses  BCG  for 3536  household  contacts  of
leprosy  patients  showed  that  28 (23%)  out of  122  contacts  diagnosed  with  leprosy,  developed  symptoms
2–10  months  after  vaccination.  This  study  describes  contacts  of leprosy  patients  in Bangladesh  who
developed  leprosy  within  12  weeks  after  receiving  a single  BCG  dose.
Methods:  A  cluster  RCT in Bangladesh  aims  to study  the  effectiveness  of  the  BCG  vaccine  versus  BCG in
combination  with  single  dose  rifampicin  (SDR)  given  2  to 3  months  after  BCG,  in  the  prevention  of  leprosy
among  contacts  of newly  diagnosed  leprosy  patients.  During  the  ﬁrst  1,5  years  of  this  ongoing  trial  we
identiﬁed  contacts  who  developed  leprosy  within  the  ﬁrst 12 weeks  after  receiving  BCG  vaccination,  the
timeframe  before  SDR  is  given.
Results:  We identiﬁed  21  contacts  who  developed  leprosy  within  12  weeks  after  BCG  vaccination  among
5196  vaccinated  contacts  (0.40%).  All  21  cases  presented  with  paucibacillary  (PB)  leprosy,  including  chil-
dren  and  adults.  About  half  of these  cases  had  previously  received  BCG  vaccination  as  indicated  by the
presence  of  a  BCG  scar;  43% presented  with  signs  of  nerve  function  impairment  and/or  Type  1 (reversal)
reaction,  and 56%  of  the  index  patients  had  multibacillary  (MB)  leprosy.
Conclusion:  An  unexpectedly  high  proportion  of  healthy  contacts  of  leprosy  patients  presented  with  PB
leprosy  within  12  weeks  after  receiving  BCG  vaccination,  possibly  as a result  of  boosted  cell-mediated
immunity  by  homologues  of  Mycobacterium  leprae  antigens  in  BCG.  Various  immunological  mecha-
nisms  could  underlie  this  phenomenon,  including  an  immune  reconstitution  inﬂammatory  syndrome
(IRIS).  Further  studies  are required  to determine  whether  BCG  vaccination  merely  altered  the  incubation
period  or  actually  changed  the  course  of the  infection  from  self-limiting,  subclinical  infection  to  manifest
disease.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) remains
he only available vaccine against tuberculosis (TB) today. It is rou-
inely administered to infants in many countries worldwide and
onfers signiﬁcant protection against severe forms of TB, mostly
iliary and meningeal in young infants. BCG-induced immunity
as been shown to decline with time and is generally thought to
ast no more than 10–15 years, differs between ages and endemic
∗ Corresponding author. Tel.: +31 10 7038473.
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
areas, and offers poor protection against contagious pulmonary TB
in adulthood [1–4].
Despite being known primarily as a vaccine against TB, BCG also
protects against leprosy (caused by Mycobacterium leprae),  espe-
cially when given to household contacts of leprosy patients [5,6]. In
fact, to date, BCG has been shown to be the best available vaccine for
prevention of leprosy, superior to other mycobacterium containing
vaccines, including combination vaccines with BCG and M.  leprae
speciﬁc vaccines [7,8]. The rationale for the use of BCG as a vaccine
against leprosy relies on the occurrence of many highly homolo-
gous antigens present in the M. bovis genome (the progenitor for the
BCG vaccine) and the M. leprae and the Mycobacterium tuberculosis
genomes [9,10], which induce cross-reactive, protective immune
responses to M. leprae following BCG vaccination.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Because of BCG’s protective effects against leprosy, Brazil has
fﬁcially recommended BCG since the early 1970s for household
ontacts of leprosy cases, as a boost to routine BCG vaccination in
ew-borns as a TB prophylactic vaccine. Since 1991, the Brazilian
inistry of Health has advised two doses of BCG to be administered
o both current household contacts and contacts of index cases
ho were diagnosed within the previous ﬁve years. This policy was
ssessed in a cohort study of 3536 contacts of 1161 leprosy patients
n Brazil [11], showing that the protection conferred by a booster
CG vaccination was 56% and was not substantially affected by pre-
ious BCG vaccination. Among the 122 new cases detected during
8 years of contact follow-up, leprosy was diagnosed in 28 of these
ontacts (23%) relatively soon after vaccination (2–10 months). Due
o incomplete follow-up, the study needs to be interpreted with
aution, and in particular the increased risk of tuberculoid leprosy
n the ﬁrst months after BCG vaccination needs further substantia-
ion.
The COLEP study in Bangladesh showed that the use of a single
ose of rifampicin (SDR) in contacts of newly diagnosed leprosy
atients reduced the overall incidence of leprosy in the ﬁrst two
ears by 57% [12]. Furthermore, this study showed that the effect
f SDR depended on the BCG status of the contact: If the contact
ad received BCG vaccination as part of a childhood vaccination
rogram (as established by the presence of a BCG-scar), the protec-
ive effect of SDR was 80% [13]. And if not, the protective effect of
CG alone was 57%.
In view of the above ﬁndings regarding BCG vaccine and SDR in
ontacts of leprosy patients, a cluster randomized controlled trial
as initiated in Bangladesh in 2012 with the aim to study the effec-
iveness of the BCG vaccine versus BCG in combination with SDR
iven 2 to 3 months after BCG, in the prevention of leprosy among
ontacts of newly diagnosed leprosy patients [14]. In this trial spe-
ial attention is given to the occurrence of clinical manifestations
f leprosy in the ﬁrst 12 weeks after the contacts received BCG vac-
ination, the timeframe before SDR is given. Here we report the
ccurrence of 21 cases of leprosy (among 5196 vaccinated con-
acts) during this ﬁrst period after BCG vaccination and describe
he characteristics of these patients and their disease symptoms.
urthermore, the possible underlying immunological mechanisms
nd implications for public health practice are discussed.
. Methods
The study is part of the MALTALEP trial [14] that is currently
onducted in the districts of Nilphamari, Rangpur, Thakurgaon
nd Panchagarh in northwest Bangladesh. Leprosy patients are
ecruited into the trial through the Rural Health Program (RHP)
f The Leprosy Mission International Bangladesh (TLMIB), located
n Nilphamari; a referral centre specialized in the detection and
reatment of leprosy. The population of the four districts is around
000,000 (2011 census [15]) and approximately 600 new leprosy
atients were detected per year between 2011 and 2013. The popu-
ation in the four districts is mainly rural, but also includes six main
owns.
The MALTALEP trial is a cluster randomized controlled trial. The
im is to study the effectiveness of the BCG vaccine alone versus
CG in combination with single-dose rifampicin (SDR) in the pre-
ention of leprosy among contacts of newly diagnosed leprosy
atients. Full details of the trial protocol were described previously
14]. In summary, contact groups of approximately 15 persons are
stablished for each of the 1300 newly diagnosed leprosy patients
index cases) included in the trial, which will result in roughly
0,000 contacts in total. The contact groups are divided randomly
ver the two arms of the trial with approximately 10,000 contacts
ach. Contacts who have been diagnosed with leprosy in the past, 33 (2015) 1562–1567 1563
are diagnosed at the intake examination (i.e. co-prevalent cases)
or are clinically considered to be leprosy suspects at intake exam-
ination, are excluded from the trial. All contacts are screened by
trained and experienced health workers at intake, to ensure they
had no apparent signs of leprosy at the time of intake. After written
informed consent was  obtained, BCG was  administered to all sub-
jects (i.e. healthy contacts) followed by SDR 8–12 weeks later in
the intervention group. Subsequent follow-up takes place one year
and two years after intake. The primary outcome is the occurrence
of clinical leprosy within two  years of intake. Individuals who are
suspected to have leprosy at any of the follow-up time points or
who present to a health clinic between follow-ups are sent to the
specialized leprosy hospital in Nilphamari or a local clinic for con-
ﬁrmation of their disease by a specialist clinician and for treatment.
Intake for the trial was started in August 2012 and is expected to
be completed in 2015.
In this paper we  report on incidental observations during the
ongoing trial of all new leprosy cases among healthy contacts who
were diagnosed within 12 weeks after receiving BCG (and before
receiving SDR) between December 2012 and May 2014. We  present
demographic and clinical data of the patients as recorded in our
database as a routine procedure for the purpose of the trial.
3. Results
A total of 21 contacts (0.40%) were diagnosed with leprosy
within 12 weeks after receiving BCG vaccination, out of 5196 con-
tacts who had received BCG and were screened after 8–12 weeks.
Table 1 shows the characteristics of the healthy contacts who
developed leprosy within 12 weeks after BCG vaccination. Of these
contacts, 10 (48%) were male and 11 (52%) female. Table 2 shows the
characteristics of the contacts who received BCG vaccination but
who did not develop leprosy. The differences between the groups
do not show statistical signiﬁcance (P > 0.05) due to the low number
of contacts with leprosy, but some of the observed group character-
istics are worth noting. The male-female distribution is also nearly
equal in this group (47% and 53%, respectively). The average age
at registration was 29 years (range: 10–70 years) among the con-
tacts who  developed leprosy, and 28 years (range: 5–90 years) in
the group of contacts who did not develop leprosy. There were 8
children (≥5 to <16 years of age) who  developed leprosy within 12
weeks after BCG vaccination, representing 38% of the new cases.
Among the contacts who  did not develop leprosy, 34% were chil-
dren. Nine (43%) of the new patients were household contacts to the
index patient, sharing either the same kitchen or roof, or both. The
remaining 12 (57%) were direct neighbours of the index patient. In
the group of contacts who  did not develop leprosy, 31% were house-
hold contacts of the index patient, a lower proportion. Nine contacts
who developed leprosy (43%) were known to be blood relatives to
the index patient, 3 were other relatives (unclear if blood relative or
not), or in-laws. In the group of contacts who  did not develop lep-
rosy, 25% were blood relatives to the index patient. Twelve (57%)
contacts developing leprosy had probably received BCG for the ﬁrst
time or no sufﬁcient response was  induced upon initial vaccination,
since no BCG scar was observed. The other 9 (43%) had a BCG scar
and were thus revaccinated. In the group of contacts that did not
develop leprosy, the proportion with a BCG scar was higher (56%).
These differences are also apparent in the proportion of leprosy
among household contacts (0.55%) and neighbours (0.34%), blood
related (0.69%) and not blood related relatives (0.30%), and those
with (0.31%) and without (0.53%) a BCG scar (Table 2).The average time from BCG to ﬁrst suspicion of leprosy by the
ﬁeld staff was 9 weeks (range: 3–11 weeks) (Table 1). Two  of these
contacts came to a clinic on their own  initiative before the planned
follow-up time, because they detected leprosy patches themselves
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Table 1
Characteristics of new cases of leprosy among contacts within 12 weeks of BCG vaccination.
Contact no. Age Sex Blood
relation to
index*
Contact
level**
BCG scar
(Y/N)
Time from BCG
to patient ﬁrst
noticing patch
(in weeks)
Time from BCG
to ﬁrst
suspicion of
leprosy by
clinician (in
weeks)
Smear result
(BI)
Classiﬁcation
(Ridley Jopling)
Nerve
involvement
(Y/N)
Reversal
reaction
(Y/N)
1 24 F N H Y Unknown 10 Negative TT N N
2  10 F N+ N Y 10 10 Negative TT N N
3  11 F Y H N Unknown 9 Refused BT N N
4  40 M N N Y Unknown 10 Negative BT N N
5  60 F Y N N Unknown 10 Negative BT Y N
6  70 M N N N 2 10 Negative TT N N
7  12 F Y H Y 7 9 Refused TT N N
8  40 F N N N 10 10 Negative BT N N
9  55 M Y N N Unknown 9 Negative BT Y Y
10  34 M Y N N 4 9 Negative BT N Y
11  12 F N+ H Y Unknown 10 Negative BT Y N
12  35 F Y H N 11 11 Negative TT N N
13  38 M N N N 4 9 Negative BT N N
14  27 F N N Y 4 9 Negative BT N Y
15  15 F N N Y 2 9 Negative BT Y N
16  16 M Y H Y Unknown 9 Negative I N N
17  12 M Y H Y 10 10 Negative I N N
18  12 M N+ H N 4 10 Negative I N N
19  12 M N N N 4 10 Negative BT Y N
20  22 M Y H N 3 3 Negative BT Y N
21  60 F N N N 4 9 Negative TT N Y
* Blood related contact: child (son/daughter), parent (father/mother), brother or sister; +Other relative: unclear if blood related or not.
** H: household contact; sharing either the same roof or kitchen, or both; N: neighbour living next door to patient‘s house.
Table 2
Characteristics of contacts with leprosy within 12 weeks after BCG vaccination, compared to those contacts who  received BCG vaccination but who did not develop leprosy.
Contact
characteristics
Contacts with leprosy Contacts without leprosy All contacts Contacts with leprosy****
N %*** N %*** N %***
Number 21 – 5175 – 5196 0.40
Male  10 48 2426 46.9 2436 0.41
Female  11 52 2749 53.1 2760 0.40
<16  years 8 38 1742 33.7 1750 0.46
≥16  years 13 62 3433 66.3 3446 0.38
Household contact* 9 43 1620 31.3 1629 0.55
Neighbour** 12 57 3555 68.7 3567 0.34
Blood  related 9 43 1301 25.1 1310 0.69
Not  blood related or unknown 12 57 3874 74.9 3886 0.30
BCG  scar 9 43 2906 56.2 2915 0.31
No  BCG scar 12 57 2269 43.8 2281 0.53
Average age at registration 29 years 28 years
* Household contact: sharing either the same roof or kitchen, or both.
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t** Neighbour next to patient.
*** 2 test: none of the differences in percentages between the two groups are stat
**** Contacts that developed leprosy in each subgroup as a percentage of the total n
3 and 9 weeks after BCG). When asking the contacts how long after
aving received BCG the patch had appeared, 7 contacts could not
rovide a clear answer as to when they ﬁrst discovered a patch
r they had only noticed it at follow-up time point when the staff
ointed it out. The remaining 14 recalled having ﬁrst seen the patch
etween 2 and 11 weeks after receiving BCG, although few could
ecollect an accurate date. All contacts with leprosy were classiﬁed
s paucibacillary (PB). According to the Ridley–Jopling classiﬁcation
16], 6 (29%) contacts were classiﬁed as tuberculoid (TT), 12 (57%)
s borderline tuberculoid (BT), and 3 (14%) as indeterminate (I). Six
ontacts (29%) presented with nerve involvement, but only one had
isability (partial foot drop). This contact (No. 9 in Table 1) asserted
hat the foot drop was present before BCG vaccination, but it was
ot noted by the staff at contact registration time. Possibly he was co-prevalent case incorrectly registered at intake. The fact that he
id not recover on steroids indicates that it was possibly a late-stage
erve function impairment. All known skin smears were negative,
wo contacts refused skin smears (because of young age).ly signiﬁcant (P > 0.05).
r of contacts in the same subgroup.
Of the 21 contacts who  developed leprosy after BCG, 4 (19%)
had Type 1 (or reversal) reaction requiring steroids on initial pre-
sentation, including the patient described above with neuritis and
partial foot drop. Three other patients (14%) who  had no nerve
involvement presented with a red, hot, swollen, anaesthetic patch
indicating a mild Type 1 reaction. One of these had a second episode
of reaction during the study requiring steroids and responded well.
In July 2014, 6 of the contacts completed multidrug therapy without
having any signs of reaction. Others were still on treatment.
Table 3 shows the characteristics of the 18 index patients of
the contacts diagnosed with leprosy in the ﬁrst 12 weeks after
BCG vaccination. In the case of two  index patients, multiple con-
tacts were found with leprosy within 12 weeks (2 and 3 contacts,
respectively). Of the remaining 16 index patients each had one con-
tact that developed leprosy. The average age at registration of the
index patient was  33 years (of which 3 index cases were younger
than 16 years). This resembles closely the average age (35 years) of
all new patients that were registered by the Rural Health Program
R.A. Richardus et al. / Vaccine 33 (2015) 1562–1567 1565
Table  3
Characteristics of the index cases according to new cases found among healthy contacts (see Table 1 for serial number of the new cases).
Index patient no. Contact patient
no.
Sex Age Classiﬁcation
(PB/MB)
Classiﬁcation
(Ridley–Jopling)
Smear result
(BI)
Duration of
symptoms
before
diagnosis (in
months)
No. of contacts
found at intake
who ever had
leprosy
No. of
co-prevalent
cases (contacts
found with
leprosy at
intake)
1 1 M 23 MB  BL 4 36 1 0
2  2 F 55 PB BT 0 12 0 0
3  3 F 30 MB  BT 0 72 0 0
4  4 M 26 PB BT 0 Not available 0 0
5  5 F 13 PB BT 0 12 0 0
6  6 M 29 PB BT 0 12 0 0
7  7 F 16 PB BT Not taken 24 1 0
8  8 M 19 PB BT 0 24 1 0
9  9 M 61 MB  BT 0 36 0 0
10  10 M 27 MB  LL 6 12 0 0
11  11 F 50 MB  BT 0 84 0 0
12  12 M 9 MB  BT 0 5 0 0
13  13 F 45 MB  BT 0 84 0 0
14
15
14  16 M 27 MB  BT 0 12 0 0
15  17 F 65 PB BT 0 12 0 0
18
16  19 F 51 MB  BT 0 120 0 0
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n 2013 (data not shown). Among the index patients 8 (44%) were
ale and 10 (56%) female. In the group of all patients registered
n 2013, the percentage of males and females was  nearly equal. Of
8 index patients, 8 (44%) were classiﬁed as PB and 10 (56%) as
B leprosy. In the group of all patients registered in 2013, these
ercentages were the other way around, 66% and 34% for PB and
B,  respectively. According to the Ridley-Jopling classiﬁcation, all
ndex patients were BT, except for one borderline lepromatous (BL)
nd one lepromatous (LL) patient. The bacterial index (BI) for most
ndex patients was negative except for the one BL patient with a BI
f 4 and the LL patient with a BI of 6. One patient refused to have a
mear taken. In the 16 index patients symptoms were detected at
n average of 38 months before diagnosis (range 5 to 120 months).
he duration of delay was 18 months (range 1 to 264 months) in the
roup of patients registered in 2013. At intake six contacts (other
han the contacts who were found to have leprosy within 12 weeks
fter BCG) of four index cases gave a history of leprosy in the past,
ut no details were available. One family represented an exception
o this ﬁnding: the father was a smear positive MB case who was
eleased from treatment in 1985 and restarted MB-MDT in 2013,
nd thus probably was the primary source of infection. One of his
ons was the index case at intake of the trial and one of the other
ons developed leprosy within 12 weeks after BCG vaccination. In
his family there were two more family members with a history of
eprosy. The father is included in Table 3 as one of the 3 contacts
ver found with leprosy.
. Discussion
We  found that 21 out of 5196 (0.40%) healthy contacts of newly
iagnosed leprosy patients in the ongoing BCG intervention trial in
angladesh developed clinical evidence of leprosy within 12 weeks
fter receiving BCG. All these 21 contacts presented with PB forms
f leprosy (I, TT and BT), with a nearly equal number of males and
emales, and including both children and adults. Nearly half (43%)
resented with signs of nerve function impairment and/or Type 1
eaction. Among the contacts with leprosy there was  a high number
ith MB index cases (56%) and with a long average duration of0 Not available 3 1
0 48 0 0
symptoms before diagnosis, possibly indicating that these contacts
experienced a high level of exposure over a long time.
The reported prevalence of leprosy in the four districts of north-
west Bangladesh in 2013 was  0.74 per 10,000 population and the
new case detection rate 0.84 per 10,000 (source: Rural Health Pro-
gram). Considering the high prevalence of leprosy in this area, it is
not surprising that there are many people with subclinical leprosy,
some of whom may  present clinical signs and symptoms for the
ﬁrst time after receiving BCG. Since all of these 21 cases were tuber-
culoid forms of leprosy, the increase of M. leprae-reactive cellular
immunity may  result from boosting of cell-mediated immunity by
homologues M. leprae antigens present in BCG. Alternatively, BCG
vaccination has been shown to induce epigenetic reprogramming
of innate cells leading to increased cytokine production in response
to related and nonrelated pathogens for up to 3 months after vac-
cination, a phenomenon called trained immunity [17].
Past studies have shown sporadically that BCG may induce clin-
ical expression of leprosy skin lesions in the short term [18,19]. In
fact, this phenomenon was discussed as early as 1960, when an
editorial in the International Journal of Leprosy addressed ‘BCG-
induced activations’ and referred to two case reports in the French
literature in 1958 [18]. Data from the Karonga Prevention Trial
between 1986 and 1989 in Malawi indicated that protection against
leprosy is afforded by a repeated BCG vaccination, even during the
ﬁrst year after revaccination, but that the case series is too small to
conﬁrm early ‘induction’ of leprosy after BCG [20]. The main reason
for paucity of information in literature about this issue is that most
trials only include long-term follow-up, often starting 1 year after
vaccination. Taking into account in particular the data described for
BCG vaccination of contacts in Brazil [11], we  anticipated a prob-
able increase in new leprosy patients in the ﬁrst year after BCG,
although we  had not expected this to occur as early (within 12
weeks) after BCG vaccination, as was  observed in the current study.
Düppre et al. [11] hypothesized that the accelerated manifestations
of tuberculoid leprosy after BCG vaccination found in their study in
Brazil, reﬂected the inﬂuence of BCG in catalyzing the existing anti-
mycobacterial immunity in subjects infected with M.  leprae before
or immediately after BCG vaccination. In line with the Brazilian
study, we  also found predominantly tuberculoid forms of leprosy.
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he incidence rate in the Brazilian study in the ﬁrst year was  higher
mong the contacts without a BCG scar than among those with a
car. We  found a similar tendency in our study, although the differ-
nce was not very large. Finally, among the contacts who  developed
eprosy soon after BCG, there was a relative high number of contacts
ith manifestations of Type 1 reaction, which was not described in
he Brazilian study.
Live vaccines, in particular BCG, have a nonspeciﬁc beneﬁcial
ffect on overall mortality when administered early in life, more
han can be explained by the targeted infection [21]. In fact children
ith a scar or a positive skin test resulting from BCG vaccination,
xhibit an overall reduction in child mortality of around 50% [22].
n adults, immunization with BCG causes increased levels of pro-
nﬂammatory cytokines TNF and IL-1 in response to BCG-related
timuli that is maintained for up to three months after vaccina-
ion [23]. The adaptive immune response after BCG vaccination
s clearly Th1-skewed and results in Mtb- and M. leprae-speciﬁc,
FN- producing CD4+ T cells that provide an early response to
hese mycobacteria and are associated with some degree of pro-
ection [24]. However, as is evident from several studies, the IFN-
esponse induced by BCG vaccination does not correlate with pro-
ection [25–27]. In addition, Th17 helper cells producing IL-17 and
L-22 are produced as well which are beneﬁcial for protection
gainst pathogens at mucosal sites [28].
In 1989, Bagshawe et al. [29] also already hypothesized that pre-
ailing immunity to mycobacterial antigens is largely responsible
or clinical manifestations of PB leprosy and that the non-speciﬁc
mmune stimulation induced by BCG vaccination can precipitate
linical signs and symptoms of leprosy in people incubating the
isease and cause upgrading of established lesions, especially in
ndeterminate or borderline leprosy. In the Karimui trial in Papua
ew Guinea [29], a 47% protection against clinical leprosy by BCG
as demonstrated. However, they provided evidence for acceler-
ted manifestation of tuberculoid leprosy in children vaccinated
hen under 5 years of age. In our study, children less than 5 years
ld were excluded, but we observed this phenomenon among all
ther ages.
Among the index cases in our study more than half had MB  lep-
osy, with an average duration of symptoms before diagnosis of
ver three years, compared with 18 months in all newly registered
eprosy patients in the Rural Health Program in 2013. We  also found
hat in the group of 21 contacts that developed leprosy, a higher
roportion were blood relative and/or a household contact of the
ndex patient than in the group of contacts that did not develop lep-
osy. These factors represents a high level of exposure over a long
uration and possibly increased susceptibility for leprosy, but deﬁ-
ite conclusions on the relationship between level of exposure and
hance of contacts to develop leprosy soon after BCG vaccination
annot be drawn until the trial is completed and immunological
nd gene expression data are available.
Presentation of leprosy as part of an immune reconstitution
nﬂammatory syndrome (IRIS) in HIV infected individuals or AIDS
atients starting their highly antiretroviral active (HAART) therapy
as been described [30,31]. Previously, Deps et al. [30] proposed
he case deﬁnition for IRIS in leprosy as leprosy and/or Type 1
eaction and erythema nodosum leprosum (ENL or Type 2 reac-
ion) developing within 6 months after initiation of HAART. They
ound that 89.5% of the leprosy/IRIS cases presented a histopatho-
ogical diagnosis of TT or BT leprosy. The mean time until onset
f IRIS after initiating HAART was 8.7 weeks. Fifty-seven percent
f the leprosy patients presented within 8–12 weeks after initi-
ting HAART [31]. Two main forms of leprosy as IRIS occurring
n the ﬁrst few months of HAART were identiﬁed [30]. The ﬁrst
ype is an inﬂammatory ‘unmasking’ of a previously untreated M.
eprae infection, the second (less commonly occurring) is a paradox-
cal clinical deterioration in pre-existing leprosy during which the 33 (2015) 1562–1567
patient developed HAART-associated Type 1 reaction. We  propose
that a comparable process leads to presentation of clinically appar-
ent leprosy after BCG vaccination of contacts of leprosy patients.
In our trial we found an unexpectedly high proportion of new
leprosy patients among apparently healthy household contacts of
leprosy patients in the ﬁrst 12 weeks after receiving BCG vacci-
nation. When all follow-up data of the trial are available, we will
compare PB/MB proportions in new cases arising among contacts at
different time points after BCG vaccination and in a group without
BCG vaccination. If a higher proportion of contacts present with
PB leprosy in the ﬁrst 12 weeks after BCG and later (in the fol-
lowing 1–2 years) a higher proportion of contacts present with
MB leprosy, this would support the theory that BCG accelerates
the immune response and reveals highly immunologically active
forms of subclinical leprosy ﬁrst. In fact BCG vaccination given to
household contacts of leprosy patients could actually identify this
important group, who  will then receive proper treatment at an early
stage. However this does not imply that BCG should be seen as a
legitimate diagnostic test for pre-clinical leprosy. Further investi-
gation including analysis of the cytokine/chemokine range induced
after BCG vaccination [32], is necessary to understand this phe-
nomenon. Differentiation of the patients through epidemiological
and immunological studies will be undertaken, in order to carefully
consider the implications of giving BCG vaccination to contacts of
newly diagnosed leprosy patients as immunoprophylaxis as part of
a leprosy control programme.
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